CHICAGO HIGHLIGHTS 2024 – GU ROUNDTABLE DISCUSSION: Renal Cell Carcinoma
OR
Chair
Dr. Christian Kollmannsberger
Panelists
Dr. Lucia Nappi
Dr. Vishal Navani
Studies/trials discussed:
- Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
